Aceragen, Inc. (ACGN)
| Market Cap | 14.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.22M |
| Shares Out | 3.13M |
| EPS (ttm) | -6.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,506 |
| Open | 4.82 |
| Previous Close | 4.85 |
| Day's Range | 4.55 - 4.91 |
| 52-Week Range | 3.66 - 16.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 29, 2023 |
About ACGN
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701 for acute pulmonary exacerbations in cystic fibrosis, as well as for melioidosis; and ACG-801 for farber disease. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is based in Exton, Pennsylvan... [Read more]
Financial Performance
Financial StatementsNews
Idera Pharmaceuticals Acquires Aceragen
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the sec...
Why Are Idera Pharmaceuticals Shares Soaring Today
Idera Pharmaceuticals Inc (NASDAQ: IDRA) shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist...
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
– Enrollment Stopped Early for Efficacy – – Enrollment Stopped Early for Efficacy –
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the firs...
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the fo...
Idera Pharmaceuticals Announces Tilsotolimod Updates
EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its sy...
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the thi...
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended Ju...
Why Idera Shares Are Skyrocketing Today
Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares are trading higher by 43% at $1.60 after it was disclosed in a Form 4 filing the company COO Daniel Soland purchased 50,000 shares of the company stock a...
Idera Will Not Continue Tilsotolimod/Ipilimumab Combo Melanoma Trial Into OS Primary Endpoint
Idera Pharmaceuticals Inc (NASDAQ: IDRA) has decided not to continue the ILLUMINATE-301 Phase 3 trial evaluating tilsotolimod in melanoma to its overall survival (OS) primary endpoint. The trial asses...
Idera Pharmaceuticals Announces Corporate Updates
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company's trial of tils...
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended Ma...
Tomslist: The 5 Weirdest Penny Stock Stories of the Week
Even the best penny stocks have their dog days. Here's a celebration of this week's weirdest plays: SNES, IDRA, SOS, TSNPD and HLLPF.
Idera Pharmaceuticals stock plunges after disappointing trial results, prompting analyst downgrade
Shares of Idera Pharmaceuticals Inc. plummeted 63.3% in active trading to pace all premarket decliners, after the immunotherapy company said the ILLUMINATE-301 pivotal registration trial of its treatm...
Why Idera Pharmaceuticals Shares Dropped 62% Lower Today
Shares of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) plunged more than 62% in the extended session Thursday after the biopharmaceutical company said its lead drug candidate Tilsotolimod failed to meet ...
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
– Objective Response Rate Endpoint Not Met – – Objective Response Rate Endpoint Not Met –
Are Options Traders Betting on a Big Move in Idera Pharmaceuticals (IDRA) Stock?
Investors need to pay close attention to Idera Pharmaceuticals (IDRA) stock based on the movements in the options market lately.
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
ILLUMINATE-301 Continues on Track for Data Later this Month ILLUMINATE-301 Continues on Track for Data Later this Month
Idera Pharmaceuticals to Present at Upcoming Conferences
EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.
Idera Pharmaceuticals (IDRA) in Focus: Stock Moves 9.4% Higher
Idera Pharmaceuticals (IDRA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Pu...
Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
– COO Role is Key to Preparedness for NDA Filing and Commercial Launch – – Clayton Fletcher , Head of Business Development & Strategic Planning , to Retire –
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
– Protects Method-of-Use in CRC and HNSCC – – Protects Method-of-Use in CRC and HNSCC –